Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to Syros Pharmaceuticals, Inc. (NasdaqGS: SYRS). Under the terms of the proposed transaction, shareholders of TYME are expected to receive approximately 0.4312 shares of Syros for each share of TYME that they own, subject to adjustment based on the amount of TYME’s net cash at closing and the number of TYME shares outstanding at closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-tyme/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

1100 Poydras St., Suite 3200

New Orleans, LA 70163

View source version on businesswire.com: https://www.businesswire.com/news/home/20220810005719/en/